Author:
Ånensen N,Hjelle S M,Van Belle W,Haaland I,Silden E,Bourdon J-C,Hovland R,Taskén K,Knappskog S,Lønning P E,Bruserud Ø,Gjertsen B T
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference51 articles.
1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE et al. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811–814.
2. Anensen N, Oyan AM, Bourdon JC, Kalland KH, Bruserud O, Gjertsen BT . (2006). A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 12: 3985–3992.
3. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122–2137.
4. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M et al. (2011). p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 13: R7.
5. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT . (2003). Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88: 416–428.
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献